Evidence map›Paper›PMID 41306063›Full record

ReviewPediatric pulmonology2025

Childhood Interstitial Lung Disease (chILD) Associated With Toxic Chemical Inhalation Exposures: A State-of-the-Art Review.

William Hadley, Robin Lacagnina, Irfan Rahman, Alicia M H Casey, Robin Deterding, Gail Deutsch, Matthew D McGraw

Abstract readReview
In one paragraph

Review in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William HadleyDepartment of Pediatrics, Division of Pediatric Pulmonology, University of Rochester Medical Center, Rochester, New York, USA.
Robin LacagninaDepartment of Pediatrics, Division of Pediatric Pulmonology, University of Rochester Medical Center, Rochester, New York, USA.
Irfan RahmanDepartment of Environmental Medicine, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-2274-2454
Alicia M H CaseyDivision of Pulmonary Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3566-9690
Robin DeterdingDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital, Aurora, Colorado, USA.ORCID 0000-0001-6890-3466
Gail DeutschSeattle Children's Research Institute, Washington, Seattle, USA.ORCID 0000-0002-0571-0285
Matthew D McGrawDepartment of Pediatrics, Division of Pediatric Pulmonology, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0002-5646-3560

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
Airway Basal Cell Stress in Environmentally-Induced Bronchiolitis ObliteransR01ES037260 · NIEHS · UNIVERSITY OF ROCHESTER · PI Matthew Daniel McGraw · 2025 to 2026
$1.4M
Mechanisms of Basal Cell Dysfunction in Chemical-induced Bronchiolitis ObliteransK08ES033290 · NIEHS · UNIVERSITY OF ROCHESTER · PI MCGRAW, MATTHEW DANIEL · 2022 to 2025
$936k
NIEHS NIH HHS K08 ES033290NIEHS NIH HHS P30 ES001247NIEHS NIH HHS R01 ES037260This study was supported by NIH NIEHS P30-ES001247 (to M.D.M.), NIEHS R01-037260 (to M.D.M.) and NIEHS K08-ES033290 (to M.D.M.).
6 · The paper itself

Abstract

rationaleThe lung is uniquely positioned for chemical inhalation exposures considering its direct communication with the environment. Childhood interstitial lung diseases (chILD) syndrome is a rare and heterogeneous group of pediatric lung diseases. Despite common inhalation exposures, few studies have associated chemical inhalation exposures with chILD. The purpose of this review was to assess for chILD syndromes following toxic chemical inhalation exposures.

methodsPubMed and Embase databases were searched with the following inclusion criteria: (1) toxic chemical inhalation exposure, (2) pediatric subjects, and (3) chILD syndrome. Studies were excluded due to incorrect (1) study design, (2) patient population, and/or (3) outcome.

resultsTwo hundred and one studies were identified, of which 142 articles were retrieved, with 74 articles included after inclusion/exclusion criteria were applied by two independent reviewers. Most of the evidence stemmed from two pandemics: humidifier disinfectant associated lung disease (HD-ILD; n = 27) and e-cigarette, or vaping product associated, lung injury (EVALI; n = 45). Common signs and symptoms included cough, shortness of breath, hypoxemia, and inspiratory crackles. Common radiographic findings included centrilobular nodules and ground-glass opacities with subpleural sparing. Histopathologic features included airway-centric injury/inflammation with foamy macrophages, as well as subpleural sparing. Oxidized lipids were common plasma biomarkers associated with both HD-ILD and EVALI. Long-term pulmonary function testing suggests a restrictive phenotype in HD-ILD but variable phenotypes in EVALI.

conclusionsChILD syndromes secondary to toxic chemical inhalation exposures manifest with common radiographic and histopathologic findings of airway-centric disease with subpleural sparing. Long-term monitoring is under-reported in toxic chemical inhalation chILD syndromes but suggests persistent lung function impairment, especially after high-dose, repeated exposures. Additional monitoring, evaluation, and reporting of chILD syndromes secondary to chemical inhalation exposure are needed to better understand its complex pathogenesis and long-term lung function implications.

Indexed as

Inhalation ExposureLung Diseases, InterstitialChildHumansVapingchemical inhalation toxic exposureschildhood interstitial lung disease (chILD)EVALIhumidifier disinfectant

Identifiers

PMID41306063
PMCPMC13032784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.